GSK respond to negative NICE recommendation on Tykerb « Kinase News

Blogroll
Tags

AstraZeneca aurora Avastin bayer Bcr-Abl bevacizumab BMS c-kit cetuximab EGFR ErbB-2 ErbB2 erbitux Exelixis Genentech GlaxoSmithKline Gleevec GSK HER1 HER2 IGF-1R Imatinib ImClone JAK2 kinase Merck-Serono Met mTOR multikinase Nexavar Novartis onyx PDGF Pfizer phase I Phase II phase iii PI3K Preclinical regulatory Research Roche sorafenib VEGF VEGFR2
Providing a resource for information on kinase inhibitors

GSK respond to negative NICE recommendation on Tykerb

Posted on October 14, 2008 by crimsoncanary

GSK have responded to the NICE recommendationi that Tyverb (lapatinib) should not be used in the NHS, except in clinical trials. The company says “we strongly believe that the wrong decision has been made for patients, doctors and the NHS”

Filed under: kinase | Tagged: EGFR, ErbB-2, ErbB2, GlaxoSmithKline, GSK, GSK-572016, GSK572016, HER2, kinase, Lapatinib, Tykerb, tyverb

« J&J indentify new JAK3 inhibitors Astex to present data on AT9283 and JAK2 program »